Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer

A phase II study

Joseph Treat, Elizabeth Johnson, Corey Langer, Chandra Belani, Brenda Haynes, Richard Greenberg, Roberto Rodriquez, Patricia Drobins, Wallace Miller, Lorraine Meehan, Ann McKeon, Jeanne Devin, Reinhard Von Roemeling, Jean Viallet

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Purpose: A phase II study was conducted to evaluate the safety and efficacy of tirapazamine combined with cisplatin for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Patients and Methods: Forty-four patients with stage IIIB/IV NSCLC were treated with a combination of tirapazamine and cisplatin. Patients received tirapazamine 260 mg/m2 administered intravenously over 2 hours, followed 1 hour later by cisplatin 75 mg/m2 administered over an additional hour, repeated every 21 days. The duration of therapy was meant to be limited to four cycles for nonresponders and eight cycles for responders. Results: Ten of 44 patients (23%) showed a partial response. The estimated median survival for all patients was 37 weeks. Toxicities were treatable and included grade 3 nausea or vomiting (25%), fatigue (27.3%), and muscle cramps (4.5%). No dose reductions were necessary. Conclusion: The results show that tirapazamine can safely be added to cisplatin. Both the median survival and response rate observed strongly suggest that tirapazamine with cisplatin is more active than cisplatin alone.

Original languageEnglish (US)
Pages (from-to)3524-3527
Number of pages4
JournalJournal of Clinical Oncology
Volume16
Issue number11
DOIs
StatePublished - Jan 1 1998

Fingerprint

tirapazamine
Non-Small Cell Lung Carcinoma
Cisplatin
Muscle Cramp
Nausea
Vomiting
Fatigue
Survival Rate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Treat, Joseph ; Johnson, Elizabeth ; Langer, Corey ; Belani, Chandra ; Haynes, Brenda ; Greenberg, Richard ; Rodriquez, Roberto ; Drobins, Patricia ; Miller, Wallace ; Meehan, Lorraine ; McKeon, Ann ; Devin, Jeanne ; Von Roemeling, Reinhard ; Viallet, Jean. / Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer : A phase II study. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 11. pp. 3524-3527.
@article{f976306d020347e5b740bf3875bfb5bb,
title = "Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study",
abstract = "Purpose: A phase II study was conducted to evaluate the safety and efficacy of tirapazamine combined with cisplatin for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Patients and Methods: Forty-four patients with stage IIIB/IV NSCLC were treated with a combination of tirapazamine and cisplatin. Patients received tirapazamine 260 mg/m2 administered intravenously over 2 hours, followed 1 hour later by cisplatin 75 mg/m2 administered over an additional hour, repeated every 21 days. The duration of therapy was meant to be limited to four cycles for nonresponders and eight cycles for responders. Results: Ten of 44 patients (23{\%}) showed a partial response. The estimated median survival for all patients was 37 weeks. Toxicities were treatable and included grade 3 nausea or vomiting (25{\%}), fatigue (27.3{\%}), and muscle cramps (4.5{\%}). No dose reductions were necessary. Conclusion: The results show that tirapazamine can safely be added to cisplatin. Both the median survival and response rate observed strongly suggest that tirapazamine with cisplatin is more active than cisplatin alone.",
author = "Joseph Treat and Elizabeth Johnson and Corey Langer and Chandra Belani and Brenda Haynes and Richard Greenberg and Roberto Rodriquez and Patricia Drobins and Wallace Miller and Lorraine Meehan and Ann McKeon and Jeanne Devin and {Von Roemeling}, Reinhard and Jean Viallet",
year = "1998",
month = "1",
day = "1",
doi = "10.1200/JCO.1998.16.11.3524",
language = "English (US)",
volume = "16",
pages = "3524--3527",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

Treat, J, Johnson, E, Langer, C, Belani, C, Haynes, B, Greenberg, R, Rodriquez, R, Drobins, P, Miller, W, Meehan, L, McKeon, A, Devin, J, Von Roemeling, R & Viallet, J 1998, 'Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study', Journal of Clinical Oncology, vol. 16, no. 11, pp. 3524-3527. https://doi.org/10.1200/JCO.1998.16.11.3524

Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer : A phase II study. / Treat, Joseph; Johnson, Elizabeth; Langer, Corey; Belani, Chandra; Haynes, Brenda; Greenberg, Richard; Rodriquez, Roberto; Drobins, Patricia; Miller, Wallace; Meehan, Lorraine; McKeon, Ann; Devin, Jeanne; Von Roemeling, Reinhard; Viallet, Jean.

In: Journal of Clinical Oncology, Vol. 16, No. 11, 01.01.1998, p. 3524-3527.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer

T2 - A phase II study

AU - Treat, Joseph

AU - Johnson, Elizabeth

AU - Langer, Corey

AU - Belani, Chandra

AU - Haynes, Brenda

AU - Greenberg, Richard

AU - Rodriquez, Roberto

AU - Drobins, Patricia

AU - Miller, Wallace

AU - Meehan, Lorraine

AU - McKeon, Ann

AU - Devin, Jeanne

AU - Von Roemeling, Reinhard

AU - Viallet, Jean

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Purpose: A phase II study was conducted to evaluate the safety and efficacy of tirapazamine combined with cisplatin for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Patients and Methods: Forty-four patients with stage IIIB/IV NSCLC were treated with a combination of tirapazamine and cisplatin. Patients received tirapazamine 260 mg/m2 administered intravenously over 2 hours, followed 1 hour later by cisplatin 75 mg/m2 administered over an additional hour, repeated every 21 days. The duration of therapy was meant to be limited to four cycles for nonresponders and eight cycles for responders. Results: Ten of 44 patients (23%) showed a partial response. The estimated median survival for all patients was 37 weeks. Toxicities were treatable and included grade 3 nausea or vomiting (25%), fatigue (27.3%), and muscle cramps (4.5%). No dose reductions were necessary. Conclusion: The results show that tirapazamine can safely be added to cisplatin. Both the median survival and response rate observed strongly suggest that tirapazamine with cisplatin is more active than cisplatin alone.

AB - Purpose: A phase II study was conducted to evaluate the safety and efficacy of tirapazamine combined with cisplatin for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Patients and Methods: Forty-four patients with stage IIIB/IV NSCLC were treated with a combination of tirapazamine and cisplatin. Patients received tirapazamine 260 mg/m2 administered intravenously over 2 hours, followed 1 hour later by cisplatin 75 mg/m2 administered over an additional hour, repeated every 21 days. The duration of therapy was meant to be limited to four cycles for nonresponders and eight cycles for responders. Results: Ten of 44 patients (23%) showed a partial response. The estimated median survival for all patients was 37 weeks. Toxicities were treatable and included grade 3 nausea or vomiting (25%), fatigue (27.3%), and muscle cramps (4.5%). No dose reductions were necessary. Conclusion: The results show that tirapazamine can safely be added to cisplatin. Both the median survival and response rate observed strongly suggest that tirapazamine with cisplatin is more active than cisplatin alone.

UR - http://www.scopus.com/inward/record.url?scp=0031734636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031734636&partnerID=8YFLogxK

U2 - 10.1200/JCO.1998.16.11.3524

DO - 10.1200/JCO.1998.16.11.3524

M3 - Article

VL - 16

SP - 3524

EP - 3527

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -